EMB-07 Market Summary

Key Factors Driving EMB-07 Growth

1. Highly Validated ROR1 Target With Broad Tumor Expression

EMB-07 targets Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1), an oncofetal antigen that is minimally expressed in normal adult tissues but is present across numerous cancers, including non-Hodgkin lymphoma, chronic lymphocytic leukemia, triple-negative breast cancer, lung adenocarcinoma, ovarian cancer, pancreatic cancer, gastric cancer, and other solid tumors. This broad expression profile creates a large potential addressable patient population and supports development across multiple indications.

2. Differentiated Safety Profile Through Reduced Cytokine Release

One of the biggest challenges for CD3-based T-cell engagers is cytokine release syndrome (CRS). Preclinical data presented at the 2024 AACR meeting demonstrated that EMB-07 achieved tumor-cell killing comparable to benchmark ROR1-targeting T-cell engagers while inducing substantially lower cytokine release both in vitro and in vivo. A favorable cytokine profile could translate into improved tolerability, broader dosing flexibility, and enhanced physician adoption if confirmed clinically.

3. Strong Preclinical Potency

AACR data showed that EMB-07 produced potent ROR1-positive tumor-cell killing and demonstrated approximately 500-fold greater tumor-lysis potency in vitro compared with a clinical-stage ROR1 antibody-drug conjugate comparator. The molecule's high-affinity ROR1 binding (~0.52 nM) and optimized design support efficient T-cell redirection against cancer cells. Such potency may improve efficacy across both hematologic and solid tumors.

4. Potential Expansion Across Both Solid Tumors and Hematologic Malignancies

Unlike many T-cell engagers that focus on a single disease, EMB-07 is being evaluated in a broad Phase I program covering:

• Relapsed/refractory lymphomas

• Triple-negative breast cancer

• Lung adenocarcinoma

• Ovarian cancer

• Pancreatic cancer

• Colorectal cancer

• Gastric cancer

• Prostate cancer

• Bladder cancer

• Uterine cancer

This multi-indication strategy significantly expands the commercial opportunity and diversifies development risk. The ongoing first-in-human study is designed to enroll approximately 150 patients across solid tumors and lymphoma cohorts.

5. Advancement Into Combination Studies

EpimAb has expanded development beyond monotherapy. In 2026, a Phase I/II study was initiated evaluating EMB-07-based combination regimens in aggressive B-cell non-Hodgkin lymphoma, including combinations with rituximab-based therapy. The planned study is expected to enroll approximately 115 patients. Combination strategies often improve efficacy and may accelerate market adoption if clinical benefit is demonstrated.

6. Proprietary Bispecific Platform and Growing Regulatory Momentum

EMB-07 was engineered using EpimAb's proprietary MAT-Fab/FIT-Ig® bispecific antibody platforms, designed to preserve monoclonal antibody-like pharmacokinetics while improving manufacturability. The program has received IND clearances in Australia, China, and, according to company disclosures, FDA IND clearance in 2025, supporting global development. A robust technology platform and expanding regulatory footprint can enhance partnering opportunities and accelerate future commercialization.

EMB-07 Recent Developments

In March 2024, EpimAb Biotherapeutics, a global clinical stage biotechnology company specializing in the development of bispecific antibodies, announced the acceptance of a late-breaking abstract featuring our novel T-cell engager (TCE) EMB-07 as a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, California.

 

“EMB-07 Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of EMB-07 for potential indication like Haematological malignancies in the 7MM. A detailed picture of EMB-07’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the EMB-07 for potential indications. The EMB-07 market report provides insights about EMB-07’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current EMB-07 performance, future market assessments inclusive of the EMB-07 market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of EMB-07 sales forecasts, along with factors driving its market.

EMB-07 Drug Summary

EMB-07 is an investigational ROR1×CD3 bispecific T-cell engager antibody developed by EpimAb Biotherapeutics for the treatment of both hematologic malignancies and solid tumors. Built using the company’s proprietary MAT-Fab (Monovalent Asymmetric Tandem Fab) platform, EMB-07 simultaneously binds receptor tyrosine kinase-like orphan receptor 1 (ROR1), a tumor-associated antigen expressed in multiple cancers, and CD3 on T cells, thereby redirecting cytotoxic T lymphocytes to recognize and eliminate ROR1-positive tumor cells. The molecule has been engineered to provide potent antitumor activity while minimizing cytokine release, a common toxicity associated with T-cell engagers. Preclinical studies demonstrated strong tumor-cell killing activity, enhanced potency compared with certain ROR1-targeting antibody-drug conjugates, and substantially lower cytokine release than benchmark ROR1-targeted bispecific molecules. EMB-07 is currently being evaluated in Phase I clinical trials in patients with advanced/metastatic solid tumors and relapsed or refractory lymphoma to assess its safety, tolerability, pharmacokinetics, and preliminary efficacy, with additional studies planned in aggressive B-cell non-Hodgkin lymphoma. The report provides EMB-07’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

 

Scope of the EMB-07 Market Report

The report provides insights into:

• A comprehensive product overview including the EMB-07 MoA, description, dosage and administration, research and development activities in potential indication like Haematological malignancies.

• Elaborated details on EMB-07 regulatory milestones and other development activities have been provided in EMB-07 market report.

• The report also highlights EMB-07‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.

• The EMB-07 market report also covers the patents information, generic entry and impact on cost cut.

• The EMB-07 market report contains current and forecasted EMB-07 sales for potential indications till 2034.

• Comprehensive coverage of the late-stage emerging therapies for respective indications.

• The EMB-07 market report also features the SWOT analysis with analyst views for EMB-07 in potential indications.

Methodology

The EMB-07 market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

 

EMB-07 Analytical Perspective by DelveInsight

• In-depth EMB-07 Market Assessment

This EMB-07 sales market forecast report provides a detailed market assessment of EMB-07 for potential indication like Haematological malignancies in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted EMB-07 sales data uptil 2034.

• EMB-07 Clinical Assessment

The EMB-07 market report provides the clinical trials information of EMB-07 for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

EMB-07 Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

EMB-07 Market Potential & Revenue Forecast

• Projected market size for the EMB-07 and its key indications

• Estimated EMB-07 sales potential (EMB-07 peak sales forecasts)

• EMB-07 Pricing strategies and reimbursement landscape

EMB-07 Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)

• EMB-07 Market positioning compared to existing treatments

• EMB-07 Strengths & weaknesses relative to competitors

EMB-07 Regulatory & Commercial Milestones

• EMB-07 Key regulatory approvals & expected launch timelines

• Commercial partnerships, licensing deals, and M&A activity

EMB-07 Clinical Differentiation

• EMB-07 Efficacy & safety advantages over existing drugs

• EMB-07 Unique selling points

 

EMB-07 Market Report Highlights

• In the coming years, the EMB-07 market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.

• The EMB-07 companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence EMB-07’s dominance.

• Other emerging products for Haematological malignancies are expected to give tough market competition to EMB-07 and launch of late-stage emerging therapies in the near future will significantly impact the market.

• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of EMB-07 in potential indications.

• Analyse EMB-07 cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.

• Our in-depth analysis of the forecasted EMB-07 sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of EMB-07 in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of EMB-07? How strong is EMB-07’s clinical and commercial performance?

• What is EMB-07’s clinical trial status in each individual indications such as Haematological malignancies and study completion date?

• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the EMB-07 Manufacturers?

• What are the key designations that have been granted to EMB-07 for potential indications? How are they going to impact EMB-07’s penetration in various geographies?

• What is the current and forecasted EMB-07 market scenario for potential indications? What are the key assumptions behind the forecast?

• What are the current and forecasted sales of EMB-07 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?

• What are the other emerging products available and how are these giving competition to EMB-07 for potential indications?

• Which are the late-stage emerging therapies under development for the treatment of potential indications?

• How cost-effective is EMB-07? What is the duration of therapy and what are the geographical variations in cost per patient?